Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hologic (HOLX)
NASDAQ:HOLX
Holding HOLX?
Track your performance easily
HOLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.36 - $84.67
Previous Close$71.65
Volume8.61M
Average Volume (3M)1.84M
Market Cap
$16.06B
Enterprise Value$16.27B
Total Cash (Recent Filing)$2.33B
Total Debt (Recent Filing)$2.55B
Price to Earnings (P/E)21.6
Beta0.43
Next Earnings
Jan 29, 2025EPS Estimate
$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.32
Shares Outstanding226,941,217
10 Day Avg. Volume2,557,670
30 Day Avg. Volume1,839,303
Standard Deviation0.09
R-Squared0.29
Alpha-0.00040
Financial Highlights & Ratios
Price to Book (P/B)3.17
Price to Sales (P/S)3.98
Price to Cash Flow (P/CF)10.90
P/FCF Ratio10.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.04
Enterprise Value/Gross Profit7.31
Enterprise Value/Ebitda38.48
Forecast
1Y Price Target
$87.08Price Target Upside21.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Hologic News
Bulls Say, Bears Say
Bulls Say
Cervical Cancer ScreeningNewly released draft USPSTF cervical cancer screening recommendations maintain cotesting as a Grade A recommended test, lifting an overhang on HOLX's market-leading AptimaHPV/ThinPrep cervical cancer screening test.
Financial PerformanceHOLX delivered strong +5.0% ex-Covid organic growth despite a temporary supply chain headwind in Skeletal Health, showcasing robust performance in Molecular Diagnostics.
Product Portfolio And Market PositionThe company has emerged stronger from COVID, delivering on a diversified position across its molecular diagnostics, women's health, and surgical franchises, with the Panther install base continuing to drive growth.
Bears Say
Cervical Screening RevenueUS cervical screening revenue could decline by 15% per year in FY25E and beyond, which would result in only a <1% headwind to HOLX's annual revenue growth and EPS.
Revenue EstimatesRevenue and EPS estimates for FY25 and FY26 have been lowered.
ValuationHOLX is trading at a slightly higher valuation compared to peers, indicating limited multiple expansion opportunities.
---
Ownership Overview
1.38% Insiders
30.46% Mutual Funds
24.46% Other Institutional Investors
16.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOLX FAQ
What was Hologic’s price range in the past 12 months?
Hologic lowest stock price was $70.36 and its highest was $84.67 in the past 12 months.
What is Hologic’s market cap?
Currently, no data Available
When is Hologic’s upcoming earnings report date?
Hologic’s upcoming earnings report date is Jan 29, 2025 which is in 38 days.
How were Hologic’s earnings last quarter?
Hologic released its earnings results on Nov 04, 2024. The company reported $1.01 earnings per share for the quarter, missing the consensus estimate of $1.013 by -$0.003.
Is Hologic overvalued?
According to Wall Street analysts Hologic’s price is currently Undervalued.
Does Hologic pay dividends?
Hologic does not currently pay dividends.
What is Hologic’s EPS estimate?
Hologic’s EPS estimate is $1.01.
How many shares outstanding does Hologic have?
Hologic has 226,941,220 shares outstanding.
What happened to Hologic’s price movement after its last earnings report?
Hologic reported an EPS of $1.01 in its last earnings report, missing expectations of $1.013. Following the earnings report the stock price went down -5.877%.
Which hedge fund is a major shareholder of Hologic?
Among the largest hedge funds holding Hologic’s share is Gotham Asset Management LLC. It holds Hologic’s shares valued at 20M.
---
Hologic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$87.08 (21.54% Upside)
$87.08 (21.54% Upside)
Blogger Sentiment
Bullish
HOLX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 26.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.89%
12-Months-Change
Fundamentals
Return on Equity
15.56%
Trailing 12-Months
Asset Growth
0.18%
Trailing 12-Months
Company Description
Hologic
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
---
HOLX Company Deck
---
HOLX Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted robust financial performance, successful growth in key segments like Molecular Diagnostics, and strategic M&A activities. However, challenges such as temporary headwinds in the Skeletal business, anticipated normalization in Breast Health growth, and external factors like IV fluid shortages were noted. Despite these challenges, the company's strong balance sheet and international growth prospects indicate a positive outlook.Read More>---
HOLX Revenue Breakdown
44.22% Diagnostics
37.79% Breast Health
15.91% GYN Surgical
2.09% Skeletal Health
---
HOLX Stock 12 Month Forecast
Average Price Target
$87.08
▲(21.54% Upside)
Technical Analysis
Best Analysts Covering HOLX
1 Year
1 Year Success Rate
8/20 ratings generated profit
1 Year Average Return
+0.34%
reiterated a buy rating 12 days ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +0.34% per trade.
---